This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in JAMA  Topic Collections  • Psychiatry  • Depression  • Tobacco  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 116 words of the full text and any section headings.

In Reply: Drs Dervaux and Laqueille provide a reminder that bupropion treatment for patients with bipolar disorder carries a risk of switching into mania. The patient in question was already prescribed bupropion at the time of the Clinical Crossroads conference and was presumably stable and being monitored for a recurrence of mania. For the reasons Dervaux and Laqueille discuss, bupropion should not be a first-line smoking cessation treatment for patients with bipolar disorder. Because the benefits of stopping smoking are so great, however, there may be circumstances—such as failure to quit with other standard pharmacotherapies plus counseling—in which a trial of bupropion is indicated. In those situations, appropriate monitoring is certainly indicated.

Financial Disclosures: None reported.

Steven A. Schroeder, MD
schroeder@medicine.ucsf.edu
Department of Medicine
University of California, San Francisco

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2009;301(20):2093.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Antidepressant Treatment and Smoking Cessation in Bipolar Disorder
Alain Dervaux and Xavier Laqueille
JAMA. 2009;301(20):2093.
EXTRACT | FULL TEXT